menu

Managing Indolent Systemic Mastocytosis: A Multidisciplinary Case Review

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Managing Indolent Systemic Mastocytosis: A Multidisciplinary Case Review

2 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of ISM by tapping into the expertise of a multidisciplinary team, including allergists, gastroenterologists, and hematologists, and increase your awareness of diagnostic criteria, the varied presentations of ISM, and new treatment options that move beyond traditional anti-mediator therapy.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Cem Akin, MD
    Professor of Internal Medicine
    University of Michigan
    Ann Arbor, MI

    Dr. Akin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Blueprint Medicines, Cogent
    Consulting fees: Blueprint Medicines, Cogent, Novartis

    Daniel J. DeAngelo, MD, PhD
    Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, MA

    Dr. DeAngelo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: AbbVie, Blueprint, GlycoMimetics, Novartis
    Consulting fees: Amgen, Autolus, Blueprint, Gilead, Jazz, Novartis, Pfizer, Servier, Takeda

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel has nothing to disclose.
    • Rebecca Barraclough has nothing to disclose.
    • Amanda Mulder has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss indolent systemic mastocytosis (ISM) diagnosis, disease, and symptom burden as it relates to treatment of ISM 
    • Develop an effective strategy to anticipate, monitor, and manage adverse effects associated with novel targeted therapies for ISM 
  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, which includes hematologists, allergists/immunologists, and gastroenterologists, as well as other healthcare providers involved in managing patients with indolent systemic mastocytosis (ISM).

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours.  Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-24-045-H01-P.  This learning activity is knowledge-based.  Your CE credits will be electronically submitted to the NABP upon successful completion of the activity.  Pharmacists with questions can contact NABP customer service at custserv@napb.net

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by an independent educational grant from Blueprint Medicines Corporation.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of ISM by tapping into the expertise of a multidisciplinary team, including allergists, gastroenterologists, and hematologists, and increase your awareness of diagnostic criteria, the varied presentations of ISM, and new treatment options that move beyond traditional anti-mediator therapy.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Cem Akin, MD
    Professor of Internal Medicine
    University of Michigan
    Ann Arbor, MI

    Dr. Akin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Blueprint Medicines, Cogent
    Consulting fees: Blueprint Medicines, Cogent, Novartis

    Daniel J. DeAngelo, MD, PhD
    Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, MA

    Dr. DeAngelo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: AbbVie, Blueprint, GlycoMimetics, Novartis
    Consulting fees: Amgen, Autolus, Blueprint, Gilead, Jazz, Novartis, Pfizer, Servier, Takeda

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel has nothing to disclose.
    • Rebecca Barraclough has nothing to disclose.
    • Amanda Mulder has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss indolent systemic mastocytosis (ISM) diagnosis, disease, and symptom burden as it relates to treatment of ISM 
    • Develop an effective strategy to anticipate, monitor, and manage adverse effects associated with novel targeted therapies for ISM 
  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, which includes hematologists, allergists/immunologists, and gastroenterologists, as well as other healthcare providers involved in managing patients with indolent systemic mastocytosis (ISM).

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours.  Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-24-045-H01-P.  This learning activity is knowledge-based.  Your CE credits will be electronically submitted to the NABP upon successful completion of the activity.  Pharmacists with questions can contact NABP customer service at custserv@napb.net

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by an independent educational grant from Blueprint Medicines Corporation.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule28 May 2024